title: Targeting the podocyte to treat glomerular kidney disease.
abstract: The majority of chronic kidney disease (CKD) cases have their origin in the glomerulus, the microvascular unit of the nephron that serves as a filter tasked with forming primary urine. This selective filtration process is determined to a large extent by the functional capacity of the podocyte, a highly differentiated cell type that enwraps the outer aspect of the glomerular capillary wall. In this short review, we describe the biology of the podocyte, its central role in the etiology of various glomerulopathies and highlight current and future opportunities to exploit the unique properties of this cell type for developing kidney-specific therapeutics.
authors.affiliation: CVMD iMED, AstraZeneca, Mölndal, Sweden. Electronic address: mark.lal@astrazeneca.com.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Lal
authors.affiliation: Evotec AG, Germany.
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Young
authors.affiliation: Evotec AG, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Andag
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology*; D058990:Molecular Targeted Therapy; D050199:Podocytes / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000503:physiopathology